Ruffer LLP Invests $2.14 Million in Catalyst Pharmaceuticals, Inc. $CPRX

Ruffer LLP bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, Holdings Channel reports. The firm bought 108,616 shares of the biopharmaceutical company’s stock, valued at approximately $2,140,000.

A number of other hedge funds have also added to or reduced their stakes in CPRX. Royal Bank of Canada raised its stake in shares of Catalyst Pharmaceuticals by 39.1% in the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock worth $5,177,000 after purchasing an additional 60,040 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Catalyst Pharmaceuticals by 5.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock worth $1,749,000 after buying an additional 3,800 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Catalyst Pharmaceuticals by 11.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Catalyst Pharmaceuticals by 99.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock valued at $12,763,000 after acquiring an additional 262,392 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in Catalyst Pharmaceuticals by 6.5% during the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock worth $1,700,000 after acquiring an additional 4,261 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.5%

Shares of CPRX stock opened at $24.20 on Thursday. The company has a 50 day moving average of $23.40 and a 200-day moving average of $21.70. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $26.58. The firm has a market cap of $2.97 billion, a P/E ratio of 14.07, a PEG ratio of 0.80 and a beta of 0.72.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.18. Catalyst Pharmaceuticals had a return on equity of 39.24% and a net margin of 37.63%.The business had revenue of $148.39 million during the quarter, compared to analyst estimates of $136.79 million. As a group, equities analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.9 EPS for the current year.

Catalyst Pharmaceuticals declared that its board has authorized a share repurchase plan on Wednesday, October 1st that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the biopharmaceutical company to purchase up to 8.3% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 26,746 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total transaction of $621,844.50. Following the sale, the director directly owned 2,360 shares of the company’s stock, valued at $54,870. This represents a 91.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Carmen Jeffrey Del sold 10,983 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total transaction of $256,233.39. Following the completion of the transaction, the insider owned 3,962 shares of the company’s stock, valued at $92,433.46. The trade was a 73.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 10.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

CPRX has been the subject of several analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Monday, December 29th. Finally, Citigroup upped their target price on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $33.20.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).